SG11202001014WA - Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant - Google Patents
Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplantInfo
- Publication number
- SG11202001014WA SG11202001014WA SG11202001014WA SG11202001014WA SG11202001014WA SG 11202001014W A SG11202001014W A SG 11202001014WA SG 11202001014W A SG11202001014W A SG 11202001014WA SG 11202001014W A SG11202001014W A SG 11202001014WA SG 11202001014W A SG11202001014W A SG 11202001014WA
- Authority
- SG
- Singapore
- Prior art keywords
- veno
- versus
- treating
- methods
- stem cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545864P | 2017-08-15 | 2017-08-15 | |
| US201762574690P | 2017-10-19 | 2017-10-19 | |
| US201862630756P | 2018-02-14 | 2018-02-14 | |
| US201862637281P | 2018-03-01 | 2018-03-01 | |
| PCT/US2018/046690 WO2019036460A1 (en) | 2017-08-15 | 2018-08-14 | METHODS OF TREATING AND / OR PREVENTING HOST GRAFT DISORDER AND / OR DIFFUSE ALVEOLAR HEMORRHAGE AND / OR VENO-OCCLUSIVE DISEASE ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001014WA true SG11202001014WA (en) | 2020-03-30 |
Family
ID=65362042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001014WA SG11202001014WA (en) | 2017-08-15 | 2018-08-14 | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11013772B2 (https=) |
| EP (1) | EP3668531A4 (https=) |
| JP (3) | JP2020531452A (https=) |
| KR (3) | KR20250150131A (https=) |
| CN (3) | CN118436776A (https=) |
| AU (1) | AU2018318982B2 (https=) |
| BR (1) | BR112020003207A2 (https=) |
| CA (1) | CA3072940A1 (https=) |
| CL (3) | CL2020000384A1 (https=) |
| GE (2) | GEP20237541B (https=) |
| IL (3) | IL272674B2 (https=) |
| JO (1) | JOP20200021A1 (https=) |
| MA (1) | MA49915A (https=) |
| MX (3) | MX2020001728A (https=) |
| MY (1) | MY210026A (https=) |
| PH (1) | PH12020500276A1 (https=) |
| SG (1) | SG11202001014WA (https=) |
| TW (3) | TWI818919B (https=) |
| WO (1) | WO2019036460A1 (https=) |
| ZA (1) | ZA202407503B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| CN112867706B (zh) | 2018-05-29 | 2024-11-15 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| WO2021108447A1 (en) * | 2019-11-26 | 2021-06-03 | Omeros Corporation | Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant |
| JP7699389B2 (ja) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| IL293550A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
| BR112022010881A2 (pt) | 2019-12-04 | 2022-08-23 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| AU2021313124A1 (en) * | 2020-07-22 | 2023-03-09 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating graft versus host disease caused by hematopoietic stem cell transplantation |
| CN113057142B (zh) * | 2021-03-30 | 2022-12-09 | 四川大学华西医院 | 一种视网膜内和/或视网膜下纤维化动物模型的构建方法 |
| TW202305010A (zh) * | 2021-04-25 | 2023-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途 |
| WO2023108028A2 (en) | 2021-12-10 | 2023-06-15 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| CN114532982A (zh) * | 2022-01-12 | 2022-05-27 | 高谋 | 评价干细胞系统移植调控补体活化作用的体系 |
| CN114686585B (zh) * | 2022-04-01 | 2023-06-30 | 中国人民解放军总医院 | Tmem65在预警和/或治疗高原病中的应用 |
| JP2025541737A (ja) | 2022-11-30 | 2025-12-23 | オメロス コーポレーション | Ｍａｓｐ－２阻害物質としての縮合ピリミジン |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| RU2271825C2 (ru) | 1999-07-21 | 2006-03-20 | Омерос Корпорейшн | Растворы и способы ингибирования боли, воспаления и разрушения хряща |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| EP1496835A4 (en) | 2002-02-01 | 2006-10-18 | Omeros Corp | COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION |
| AU2003249317B2 (en) | 2002-07-19 | 2007-08-02 | Institute Of Materials Research And Engineering | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| EP1625166B1 (en) | 2003-05-12 | 2015-04-08 | Helion Biotech ApS | Antibodies to masp-2 |
| CN101065148A (zh) * | 2003-07-03 | 2007-10-31 | 奥索-麦克尼尔药品公司 | 结合补体级联抑制剂 |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| JP2008540385A (ja) * | 2005-05-06 | 2008-11-20 | ラボラトワール セローノ ソシエテ アノニム | 疾患を治療するための免疫グロブリンドメイン含有細胞表面認識分子の使用 |
| EP2606058B1 (en) * | 2010-07-21 | 2017-03-08 | Eastern Virginia Medical School | Peptide compounds to regulate the complement system |
| US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| EP2704743B1 (en) * | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| AU2014209350B8 (en) | 2013-01-23 | 2019-04-18 | Department Of Veterans Affairs (Us) | Targeting constructs based on natural antibodies and uses thereof |
| SMT202000659T1 (it) * | 2013-10-17 | 2021-01-05 | Omeros Corp | Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2 |
| CN106687123A (zh) * | 2014-06-05 | 2017-05-17 | 科罗拉多州大学评议会 | Map44多肽和基于天然抗体的构建体及其用途 |
| CA2988313A1 (en) * | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| CN108472347B (zh) * | 2015-11-09 | 2023-09-05 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
-
2018
- 2018-08-13 TW TW107128182A patent/TWI818919B/zh active
- 2018-08-13 TW TW112136719A patent/TWI881481B/zh active
- 2018-08-13 TW TW114113955A patent/TW202529812A/zh unknown
- 2018-08-14 MX MX2020001728A patent/MX2020001728A/es unknown
- 2018-08-14 MY MYPI2024000764A patent/MY210026A/en unknown
- 2018-08-14 EP EP18845831.9A patent/EP3668531A4/en active Pending
- 2018-08-14 MA MA049915A patent/MA49915A/fr unknown
- 2018-08-14 GE GEAP201815297A patent/GEP20237541B/en unknown
- 2018-08-14 SG SG11202001014WA patent/SG11202001014WA/en unknown
- 2018-08-14 KR KR1020257031404A patent/KR20250150131A/ko active Pending
- 2018-08-14 GE GEAP202315297A patent/GEAP202315297A/en unknown
- 2018-08-14 CN CN202410427006.0A patent/CN118436776A/zh active Pending
- 2018-08-14 KR KR1020247021113A patent/KR102863808B1/ko active Active
- 2018-08-14 IL IL272674A patent/IL272674B2/en unknown
- 2018-08-14 US US16/103,332 patent/US11013772B2/en active Active
- 2018-08-14 IL IL315724A patent/IL315724A/en unknown
- 2018-08-14 KR KR1020207006893A patent/KR102679441B1/ko active Active
- 2018-08-14 IL IL315726A patent/IL315726A/en unknown
- 2018-08-14 BR BR112020003207-7A patent/BR112020003207A2/pt unknown
- 2018-08-14 WO PCT/US2018/046690 patent/WO2019036460A1/en not_active Ceased
- 2018-08-14 CA CA3072940A patent/CA3072940A1/en active Pending
- 2018-08-14 AU AU2018318982A patent/AU2018318982B2/en active Active
- 2018-08-14 JP JP2020508563A patent/JP2020531452A/ja active Pending
- 2018-08-14 JO JOP/2020/0021A patent/JOP20200021A1/ar unknown
- 2018-08-14 CN CN202410427005.6A patent/CN118634322A/zh active Pending
- 2018-08-14 CN CN201880052958.1A patent/CN111278449B/zh active Active
-
2020
- 2020-02-06 PH PH12020500276A patent/PH12020500276A1/en unknown
- 2020-02-12 MX MX2024012815A patent/MX2024012815A/es unknown
- 2020-02-12 MX MX2024012816A patent/MX2024012816A/es unknown
- 2020-02-14 CL CL2020000384A patent/CL2020000384A1/es unknown
-
2021
- 2021-04-09 US US17/226,987 patent/US11896621B2/en active Active
-
2022
- 2022-01-25 CL CL2022000195A patent/CL2022000195A1/es unknown
- 2022-01-25 CL CL2022000194A patent/CL2022000194A1/es unknown
-
2023
- 2023-06-21 JP JP2023101662A patent/JP2023123627A/ja active Pending
- 2023-12-06 US US18/531,118 patent/US20240293465A1/en active Pending
-
2024
- 2024-10-02 ZA ZA2024/07503A patent/ZA202407503B/en unknown
-
2025
- 2025-04-24 JP JP2025072148A patent/JP2025108730A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202001014WA (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
| IL258865A (en) | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 | |
| PL3145517T3 (pl) | Funkcjonalne oligodendrocyty pochodzące z pluripotencjalnych komórek macierzystych oraz sposoby ich otrzymywania i stosowania | |
| PT3551748T (pt) | Células estaminais do mesênquima derivadas de tecido perinatal: método de preparação e suas utilizações | |
| IL263341A (en) | Stem cell material, compounds and methods of use | |
| IL263265A (en) | Use of mesenchymal stem cells and their parts | |
| PL3654896T3 (pl) | Artykuły chłonne z jednolitymi zapięciami haczykowymi oraz sposoby wytwarzania takich artykułów | |
| AP2016009581A0 (en) | Composition and method for stabilizing and maintaining the viability of hardy microorganisms | |
| SG11201706090SA (en) | Cell culturing method and kit | |
| IL277878A (en) | Preparations and methods for stem cell transplantation | |
| IL256093B (en) | Method for multiplying and/or differentiating hematopoietic stem cells into progenitors and uses thereof | |
| IL260858B (en) | Mesenchymal stem cells as vaccine adjuvants and methods for using the same | |
| SG10201913752PA (en) | Methods and compositions for stem cell transplantation | |
| PL3535511T3 (pl) | Zmniejszanie obrostu mikrobiologicznego w rurach | |
| IL273311A (en) | Biological material containing stem cells derived from adipose tissue and methods for its preparation | |
| SG11202004935UA (en) | Cell culture methods | |
| IL249376A0 (en) | Proliferation and transplantation of stem cells using notch1 and/or notch2 agonists | |
| IL273258A (en) | Biological material containing stem cells derived from adipose tissue and methods for its preparation | |
| EP3139913A4 (en) | Methods and compositions for non-cytotoxic stem cell transplantation | |
| EP3201337A4 (en) | Methods and compositions for use of non-coding rna in cell culturing and selection | |
| PL3630946T3 (pl) | Sposoby hodowli komórkowych | |
| IL257524B1 (en) | Short interfering RNA and its use in methods and preparations for inhibiting the expression of ankyrin horseradish protein gene regulated by Nutz | |
| IL273934A (en) | Methods for treating contractured muscle and related cultured cells | |
| IL255664A0 (en) | Hematopoietic stem cells with enhanced properties | |
| HK1244511A1 (zh) | 与嗜酸细胞食管炎相关的基因改变的诊断和治疗 |